Up to now, the United States Food and Drug Administration (FDA) has successively approved 3 ICI monotherapies for the first-line treatment of advanced NSCLC patients with at least 50% tumor cells expressing PD-L1 (US Food and Drug Administration, 2016; US Food and Drug Administration, 2021a; US Food and Drug Administration, 2021b). The gene discussed is CD274; the disease is non-small cell lung carcinoma.